- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pfizer (PFE)
Find here information about Pfizer share price (PFE). You can find more details about Sanofi shares (NYSE: PFE) by going to one of the sections listed on this page such as historical data, price charts, Sanofi stock price technical analysis and more.
NYSE
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.83
25.34
52 wk Range
20.92
27.69
High dividend Yield
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
24.8325.34
52 wk Range
20.9227.69
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(6.91%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(6.91%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PFE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
28.62
Upside
+15.04%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 15 consecutive years
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Pfizer Company Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Pfizer Inc SWOT Analysis
Pipeline Potential | Explore Pfizer's strategic focus on oncology and weight management, with promising developments in SSGJ-707 for non-small cell lung cancer treatment |
Financial Health | Discover Pfizer's robust financials, including a 74% gross profit margin and 6.8% dividend yield, with maintained revenue guidance of $61-64 billion for FY2025 |
Market Positioning | Analysts view Pfizer as undervalued compared to peers, with price targets ranging from $24 to $36, reflecting potential for growth and margin expansion |
Strategic Challenges | Learn about Pfizer's response to setbacks in clinical trials and its ambitious cost optimization strategy, aiming for $4.5 billion in net savings by 2025 |
Pfizer Inc Earnings Call Summary for Q3/2025
- Pfizer reported Q3 2025 adjusted EPS of $0.87, beating forecasts by 31.82%, while revenue fell slightly short at $16.7 billion with a 7% operational YoY decrease.
- Despite strong earnings, Pfizer's stock dipped 1.05% pre-market to $24.40, reflecting investor concerns over revenue shortfalls in COVID-19 products.
- Non-COVID products showed 4% operational growth, with notable performance from Nurtec and Vyndaqel, partially offsetting overall revenue decline.
- Management raised full-year 2025 EPS guidance to $3.00-$3.15 and maintained revenue outlook of $61-64 billion, signaling confidence in profitability.
- CEO Albert Bourla expressed optimism about the company's future, while CFO Dave Denton emphasized disciplined expense management and cost improvement programs.
Last Updated: 04/11/2025, 17:02
Read Full TranscriptCompare PFE to Peers and Sector
Metrics to compare | PFE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPFEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.4x | 24.8x | −0.6x | |
PEG Ratio | 0.11 | −0.54 | 0.00 | |
Price/Book | 1.5x | 1.5x | 2.6x | |
Price / LTM Sales | 2.3x | 1.8x | 3.2x | |
Upside (Analyst Target) | 10.5% | 0.0% | 41.8% | |
Fair Value Upside | Unlock | 5.3% | 5.1% | Unlock |
Analyst Ratings
10 Buy
15 Hold
1 Sell
Ratings:
26 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 28.62
(+15.04% Upside)
Earnings
Latest Release
Nov 04, 2025
EPS / Forecast
0.87 / 0.66
Revenue / Forecast
16.70B / 16.80B
People Also Watch
FAQ
What Is the Pfizer (PFE) Share Price Today?
The live Pfizer share price today is 24.88
What Stock Exchange Does Pfizer (PFE) Trade On?
Pfizer is listed and trades on the New York Stock Exchange.
What Is the Ticker (Stock Symbol) for Pfizer?
The stock symbol (also called a 'ticker') for Pfizer is "PFE."
Does Pfizer Pay Dividends? What’s The Current PFE Dividend Yield?
Yes, PFE Pays Dividends to its Shareholders. The current Pfizer dividend yield is 6.91%.
What Is the Current Pfizer Market Cap?
As of today, Pfizer market capitalisation is 141.46B.
What Is Pfizer's (PFE) Earnings Per Share (TTM)?
The Pfizer EPS is currently 1.72 (Trailing Twelve Months).
When Is the Next Pfizer Earnings Date?
Pfizer's next earnings report will be released on 03 Feb 2026.
Is PFE a Buy or Sell From a Technical Analyst Perspective?
Based on today's Pfizer moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Pfizer Stock Split?
Pfizer has split 6 times. (See the PFE stock split history page for full effective split date and price information.)
How Many Employees Does Pfizer Have?
Pfizer has 81000 employees.
What is the current trading status of Pfizer (PFE)?
As of 24 Dec 2025, Pfizer (PFE) is trading at a price of 24.88, with a previous close of 24.88. The stock has fluctuated within a day range of 24.83 to 25.34, while its 52-week range spans from 20.92 to 27.69.
What Is Pfizer (PFE) Price Target According to Analysts?
The average 12-month price target for Pfizer is USD28.62292, with a high estimate of USD36.16 and a low estimate of USD23. 10 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +15.04% Upside potential.
What Is the PFE Premarket Price?
PFE's last pre-market stock price is 24.96. The pre-market share volume is 5,100.00, and the stock has decreased by 0.08, or 0.32%.
What Is the PFE After Hours Price?
PFE's last after hours stock price is 24.94, the stock has decreased by 0.06, or 0.24%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.